These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 37292282)

  • 21. Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment.
    Chen L; Zody MC; Di Germanio C; Martinelli R; Mediavilla JR; Cunningham MH; Composto K; Chow KF; Kordalewska M; Corvelo A; Oschwald DM; Fennessey S; Zetkulic M; Dar S; Kramer Y; Mathema B; Germer S; Stone M; Simmons G; Busch MP; Maniatis T; Perlin DS; Kreiswirth BN
    mSphere; 2021 Aug; 6(4):e0048021. PubMed ID: 34431691
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of MW06, a human monoclonal antibody with cross-neutralization activity against both SARS-CoV-2 and SARS-CoV.
    Jiang W; Wang J; Jiao S; Gu C; Xu W; Chen B; Wang R; Chen H; Xie Y; Wang A; Li G; Zeng D; Zhang J; Zhang M; Wang S; Wang M; Gui X
    MAbs; 2021; 13(1):1953683. PubMed ID: 34313527
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting SARS-CoV2 Spike Protein Receptor Binding Domain by Therapeutic Antibodies.
    Hussain A; Hasan A; Nejadi Babadaei MM; Bloukh SH; Chowdhury MEH; Sharifi M; Haghighat S; Falahati M
    Biomed Pharmacother; 2020 Oct; 130():110559. PubMed ID: 32768882
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modeling SARS-CoV-2 spike/ACE2 protein-protein interactions for predicting the binding affinity of new spike variants for ACE2, and novel ACE2 structurally related human protein targets, for COVID-19 handling in the 3PM context.
    Tragni V; Preziusi F; Laera L; Onofrio A; Mercurio I; Todisco S; Volpicella M; De Grassi A; Pierri CL
    EPMA J; 2022 Mar; 13(1):149-175. PubMed ID: 35013687
    [TBL] [Abstract][Full Text] [Related]  

  • 25. RBD-mRNA vaccine induces broadly neutralizing antibodies against Omicron and multiple other variants and protects mice from SARS-CoV-2 challenge.
    Shi J; Zheng J; Zhang X; Tai W; Odle AE; Perlman S; Du L
    Transl Res; 2022 Oct; 248():11-21. PubMed ID: 35489692
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dissection of Antibody Responses of Gam-COVID-Vac-Vaccinated Subjects Suggests Involvement of Epitopes Outside RBD in SARS-CoV-2 Neutralization.
    Byazrova M; Gattinger P; Astakhova E; Hofer G; Khaitov M; Filatov A; Valenta R
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982183
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The impact of spike N501Y mutation on neutralizing activity and RBD binding of SARS-CoV-2 convalescent serum.
    Lu L; Chu AW; Zhang RR; Chan WM; Ip JD; Tsoi HW; Chen LL; Cai JP; Lung DC; Tam AR; Yau YS; Kwan MY; To WK; Tsang OT; Lee LL; Yi H; Ip TC; Poon RW; Siu GK; Mok BW; Cheng VC; Chan KH; Yuen KY; Hung IF; To KK
    EBioMedicine; 2021 Sep; 71():103544. PubMed ID: 34419925
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epitope Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV-2 Variants of Concern.
    Deshpande A; Harris BD; Martinez-Sobrido L; Kobie JJ; Walter MR
    Front Immunol; 2021; 12():691715. PubMed ID: 34149735
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Human antibody recognition and neutralization mode on the NTD and RBD domains of SARS-CoV-2 spike protein.
    Otsubo R; Minamitani T; Kobiyama K; Fujita J; Ito T; Ueno S; Anzai I; Tanino H; Aoyama H; Matsuura Y; Namba K; Imadome KI; Ishii KJ; Tsumoto K; Kamitani W; Yasui T
    Sci Rep; 2022 Nov; 12(1):20120. PubMed ID: 36418391
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Structural insights for neutralization of Omicron variants BA.1, BA.2, BA.4, and BA.5 by a broadly neutralizing SARS-CoV-2 antibody.
    Kumar S; Patel A; Lai L; Chakravarthy C; Valanparambil R; Reddy ES; Gottimukkala K; Davis-Gardner ME; Edara VV; Linderman S; Nayak K; Dixit K; Sharma P; Bajpai P; Singh V; Frank F; Cheedarla N; Verkerke HP; Neish AS; Roback JD; Mantus G; Goel PK; Rahi M; Davis CW; Wrammert J; Godbole S; Henry AR; Douek DC; Suthar MS; Ahmed R; Ortlund E; Sharma A; Murali-Krishna K; Chandele A
    Sci Adv; 2022 Oct; 8(40):eadd2032. PubMed ID: 36197988
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SARS-CoV-2 Antibody Effectiveness Is Influenced by Non-Epitope Mutation/Binding-Induced Denaturation of the Epitope 3D Architecture.
    Malisheni MM; Bates M; Rizvanov AA; MacAry PA
    Pathogens; 2022 Nov; 11(12):. PubMed ID: 36558771
    [TBL] [Abstract][Full Text] [Related]  

  • 32. XAV-19, a Swine Glyco-Humanized Polyclonal Antibody Against SARS-CoV-2 Spike Receptor-Binding Domain, Targets Multiple Epitopes and Broadly Neutralizes Variants.
    Vanhove B; Marot S; So RT; Gaborit B; Evanno G; Malet I; Lafrogne G; Mevel E; Ciron C; Royer PJ; Lheriteau E; Raffi F; Bruzzone R; Mok CKP; Duvaux O; Marcelin AG; Calvez V
    Front Immunol; 2021; 12():761250. PubMed ID: 34868003
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Two Opposing Roles of SARS-CoV-2 RBD-Reactive Antibodies in Pre-Pandemic Plasma Samples From Elderly People in ACE2-Mediated Pseudovirus Infection.
    Sim KY; Ko GH; Bae SE; Choi KY; Lee JS; Kim BC; Lee KH; Song MR; Park SG
    Front Immunol; 2021; 12():813240. PubMed ID: 35087532
    [TBL] [Abstract][Full Text] [Related]  

  • 34. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants.
    Wang Z; Schmidt F; Weisblum Y; Muecksch F; Barnes CO; Finkin S; Schaefer-Babajew D; Cipolla M; Gaebler C; Lieberman JA; Oliveira TY; Yang Z; Abernathy ME; Huey-Tubman KE; Hurley A; Turroja M; West KA; Gordon K; Millard KG; Ramos V; Da Silva J; Xu J; Colbert RA; Patel R; Dizon J; Unson-O'Brien C; Shimeliovich I; Gazumyan A; Caskey M; Bjorkman PJ; Casellas R; Hatziioannou T; Bieniasz PD; Nussenzweig MC
    bioRxiv; 2021 Jan; ():. PubMed ID: 33501451
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Binding and neutralizing abilities of antibodies towards SARS-CoV-2 S2 domain.
    Gao X; Fan L; Zheng B; Li H; Wang J; Zhang L; Li J; Zhu F
    Hum Vaccin Immunother; 2022 Nov; 18(5):2055373. PubMed ID: 35417303
    [TBL] [Abstract][Full Text] [Related]  

  • 36. LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants.
    Westendorf K; Žentelis S; Wang L; Foster D; Vaillancourt P; Wiggin M; Lovett E; van der Lee R; Hendle J; Pustilnik A; Sauder JM; Kraft L; Hwang Y; Siegel RW; Chen J; Heinz BA; Higgs RE; Kallewaard NL; Jepson K; Goya R; Smith MA; Collins DW; Pellacani D; Xiang P; de Puyraimond V; Ricicova M; Devorkin L; Pritchard C; O'Neill A; Dalal K; Panwar P; Dhupar H; Garces FA; Cohen CA; Dye JM; Huie KE; Badger CV; Kobasa D; Audet J; Freitas JJ; Hassanali S; Hughes I; Munoz L; Palma HC; Ramamurthy B; Cross RW; Geisbert TW; Menacherry V; Lokugamage K; Borisevich V; Lanz I; Anderson L; Sipahimalani P; Corbett KS; Yang ES; Zhang Y; Shi W; Zhou T; Choe M; Misasi J; Kwong PD; Sullivan NJ; Graham BS; Fernandez TL; Hansen CL; Falconer E; Mascola JR; Jones BE; Barnhart BC
    bioRxiv; 2022 Mar; ():. PubMed ID: 33972947
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of three conserved linear B cell epitopes on the SARS-CoV-2 spike protein.
    Wang A; Tian Y; Liu H; Ding P; Chen Y; Liang C; Du Y; Jiang D; Zhu X; Yin J; Zhang G
    Emerg Microbes Infect; 2022 Dec; 11(1):2120-2131. PubMed ID: 35916768
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A highly sensitive bead-based flow cytometric competitive binding assay to detect SARS-CoV-2 neutralizing antibody activity.
    Yao X; Zhang Z; Mei Q; Li S; Xing L; Long Y; Zhang D; Wang J; Wang X; Xie B; Yang B; Gao Y; Wu C; Meng Q
    Front Immunol; 2022; 13():1041860. PubMed ID: 36532082
    [TBL] [Abstract][Full Text] [Related]  

  • 39. LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants.
    Westendorf K; Žentelis S; Wang L; Foster D; Vaillancourt P; Wiggin M; Lovett E; van der Lee R; Hendle J; Pustilnik A; Sauder JM; Kraft L; Hwang Y; Siegel RW; Chen J; Heinz BA; Higgs RE; Kallewaard NL; Jepson K; Goya R; Smith MA; Collins DW; Pellacani D; Xiang P; de Puyraimond V; Ricicova M; Devorkin L; Pritchard C; O'Neill A; Dalal K; Panwar P; Dhupar H; Garces FA; Cohen CA; Dye JM; Huie KE; Badger CV; Kobasa D; Audet J; Freitas JJ; Hassanali S; Hughes I; Munoz L; Palma HC; Ramamurthy B; Cross RW; Geisbert TW; Menachery V; Lokugamage K; Borisevich V; Lanz I; Anderson L; Sipahimalani P; Corbett KS; Yang ES; Zhang Y; Shi W; Zhou T; Choe M; Misasi J; Kwong PD; Sullivan NJ; Graham BS; Fernandez TL; Hansen CL; Falconer E; Mascola JR; Jones BE; Barnhart BC
    Cell Rep; 2022 May; 39(7):110812. PubMed ID: 35568025
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serological testing for SARS-CoV-2 antibodies in clinical practice: A comparative diagnostic accuracy study.
    Horn MP; Jonsdottir HR; Brigger D; Damonti L; Suter-Riniker F; Endrich O; Froehlich TK; Fiedler M; Largiadèr CR; Marschall J; Weber B; Eggel A; Nagler M
    Allergy; 2022 Jul; 77(7):2090-2103. PubMed ID: 34986501
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.